People in the News: Borbeau Joins BD; Maag New CEO of XDx; NanoString Appoints James Johnson as CFO
BD Diagnostics said that Paul Borbeau has joined the company as director of North American scientific affairs for diagnostic systems.
Borbeau most recently served as director of microbiology for Geisinger Medical Laboratories. He is also currently the associate editor of the Journal of Clinical Microbiology. Borbeau received a PhD in microbiology from Temple University School of Medicine and completed post-graduate training in clinical microbiology at Hartford Hospital in Conn.
XDx has appointed Peter Maag as president and CEO.
Prior to joining XDx, Maag was president of Novartis Diagnostics, where he accelerated growth in the company's blood screening business, which screens 80 percent of the US and 30 percent of the global blood supply. Prior to that, Maag served as country president for Novartis Pharma in Germany. He has also held various senior roles at Novartis, including country president in Korea, head of infectious disease in Switzerland, and head of strategy for the pharma division. Prior to joining Novartis, Maag worked at McKinsey & Company in New Jersey and Germany. He holds a PhD from the University of Berlin in Germany.
NanoString Technologies said this week that it has appointed James Johnson as chief financial officer.
Johnson will assume this role from Wayne Burns, who will remain with the company as senior vice president of operations and finance.
Johnson joins NanoString from Relypsa, where was CFO. Prior to that he spent nearly ten years with ZymoGenetics, where was most recently executive vice president, CFO, treasurer, and secretary. He has also held financial positions at Targeted Genetics and Immunex.
CareDx
In Brief This Week: T2 Biosystems, Novacyt, OpGen, Dante Genomics, Nautilus Biotechnology, More
Pierian, Seven Bridges, UgenTec Acquired, Merged to Become Velsera
Hera Biotech Aims to Diagnose Endometriosis With Single-Cell Targeted Gene Expression Panel
DermTech Stock Soars on News of Additional Coverage for Melanoma Detection Test